Zobrazeno 1 - 10
of 51
pro vyhledávání: ''
Autor:
Pierrick Coupé, Aurélie Ruet, Julie Charré-Morin, Bruno Brochet, D. Lamargue, Aurore Saubusse, Amandine Moroso, Ismail Koubiyr, Mathilde Deloire
Publikováno v:
Journal of the Neurological Sciences
Journal of the Neurological Sciences, Elsevier, 2020, 415, pp.116929-. ⟨10.1016/j.jns.2020.116929⟩
Journal of the Neurological Sciences, Elsevier, 2020, 415, pp.116929-. ⟨10.1016/j.jns.2020.116929⟩
International audience; Background: Specific cognitive rehabilitation (SCR) has been suggested for multiple sclerosis (MS). A randomized controlled trial (RCT) evaluating the therapeutic effects of SCR is necessary.Objective: To demonstrate the super
Autor:
Andrew Siyoon Ham, Spencer K. Hutto, Rebecca L. Gillani, Andre C. Vogel, Marcelo Matiello, Tamara B. Kaplan, Kristin M. Galetta, Gladia C. Hotan, Farrah J. Mateen, Ilena C. George, Dylan R. Rice, Eric C. Klawiter
Publikováno v:
Journal of the Neurological Sciences. 428:117612
We perform a randomized trial to test the impact of electronic pill bottles with audiovisual reminders on oral disease modifying therapy (DMT) adherence in people with MS (PwMS).Adults with multiple sclerosis (MS) taking an oral DMT were randomized 1
Autor:
Philippa Miller, Andrew Soundy
Publikováno v:
Journal of the Neurological Sciences. 381:41-54
Aim The clinical aim was to provide up-to-date evidence-based recommendations for the treatment of MS-related fatigue (MSRF). The scientific aim was to prioritise topics for future randomised clinical trials with sufficient power. Methods A systemati
Autor:
Patrick Vermersch, E. Sartori, Benoit Dupuy, Philippe Cabre, Marc Debouverie, David Brassat, Patrick Hautecoeur, Jérôme De Seze, Jean Pelletier, Pierre Clavelou, Irène Coman, Christian Creveuil, Pierre Lebiez, Ayman Tourbah, Olivier Heinzlef, Gilles Defer, Bruno Brochet, Christine Lebrun-Frenay, David Daplaud, Laure Peyro Saint Paul, Giovanni Castelnovo
Publikováno v:
Journal of the Neurological Sciences. 363:69-76
Memantine, an uncompetitive antagonist of N-methyl- d -aspartate (NMDA)-type glutamate receptors that was approved for the treatment of moderate to severe Alzheimer's disease, has been negatively evaluated for the treatment of cognitive disorders of
Autor:
Farrah J. Mateen, Lindsay Pothier, Deus Buma, Andre C. Vogel, Seif Sharif Ismail, Faraja Chiwanga, Kigocha Okeng'o
Publikováno v:
J Neurol Sci
BACKGROUND: Sub-Saharan Africa has a high stroke incidence and post-stroke morbidity. An inexpensive pharmacological treatment for stroke recovery would be beneficial to patients in the region. Fluoxetine, currently on the World Health Organization E
Autor:
Joseph Jankovic, Cynthia L. Comella, Marc Schwartz, Mark Stacy, Charles H. Adler, Aubrey Manack Adams, Mitchell F. Brin, David Charles
Publikováno v:
Journal of the Neurological Sciences. 349(1-2):84-93
BackgroundThe Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE; NCT00836017) is a prospective, observational, multicenter, real-world registry designed to assess the safety, effectiveness, and treatment util
Publikováno v:
Journal of the Neurological Sciences. 347:23-33
Vascular comorbidities are common in the general population and are associated with adverse health outcomes. In people with multiple sclerosis (MS), an increasing amount of evidence suggests that vascular comorbidities are also common, but an associa
Publikováno v:
Journal of the Neurological Sciences. 362:66-68
In clinical trials drop out bias reduces the validity of results. This is a particular problem in long-term multiple sclerosis (MS) studies, particularly when patients become progressively disabled and have increasing difficulty attending assessment
Autor:
John D. Fisk, Marcus W. Koch, Philip Jacobs, Jamie Greenfield, Virender Bhan, Luanne M. Metz, Murray G. Brown, T. Jock Murray
Publikováno v:
Journal of the Neurological Sciences. 341:51-54
The nine hole peg test (9HPT) is an emerging outcome measure in clinical trials in multiple sclerosis (MS). In this study we investigated how performance on the 9HPT at baseline is related to annualized direct MS related cost.We enrolled patients wit
Autor:
Jin Young Ahn, Eungseok Oh, Joong-Seok Kim, Hee Tae Kim, Jinse Park, Jinyoung Youn, Jin Whan Cho, Kyung Jin Shin, Wooyoung Jang, Ji Sun Kim, Ki Wook Oh
Publikováno v:
Journal of the Neurological Sciences. 337:47-54
Background Numerous animal studies and clinical trials have demonstrated that erythropoietin (EPO) has therapeutic effects in ischemic and degenerative diseases. However, few clinical trials have investigated the effect of EPO in Parkinson's disease